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Abstract
Introduction There are no previous published reports on primary pediatric tumors of the central nervous system (CNS) in Qatar.
We undertook this retrospective cohort study to review the diagnosis of CNS tumors in children in Qatar to analyze the
presentation characteristics including symptoms, referral pathways, and time to diagnosis.
Methods All children registered with Pediatric Neuro-Oncology service (PNOS) were included in the study. Data from the time
of diagnosis (October 2007 to February 2020) were reviewed retrospectively. Presenting symptoms were recorded and pre-
diagnosis symptom interval (PSI) was calculated from the onset of the first symptom to the date of diagnostic imaging.
Results Of the 61 children registered with PNOS during the study period, 51 were included in the final analysis. Ten children were
excluded because theywere either diagnosed outside Qatar (n = 7) or were asymptomatic at the time of diagnosis (n = 3). Themedian age
was 45 (range 1–171) months. Common tumor types included low-grade glioma (LGG) (47.1%) and medulloblastoma/primitive neuro-
ectodermal tumors (PNET) (23.5%).Nine children had an underlying neurocutaneous syndrome. Thirty-eight patients (74.5%) had at least
one previous contact with healthcare (HC) professional, but 27 (52%) were still diagnosed through the emergency department (ED).
Presenting symptoms included headache, vomiting (36.2%), oculo-visual symptoms (20.6%), motor weakness (18.9%), seizures, ataxia
(17.2% each), irritability, cranial nerve palsies (12% each), and endocrine symptoms (10.3%). Median PSI was 28 days (range 1–845
days) for all CNS tumors. Longest PSIwas seenwith germcell tumors (median 146 days), supratentorial location (39 days), and age above
3 years (30 days). Tumor characteristics of biological behavior (high-grade tumor) and location (infratentorial) were significantly asso-
ciated with shorter PSI, as were presenting symptoms of ataxia, head tilt, and altered consciousness.
Conclusions Although overall diagnostic times were acceptable, some tumor types were diagnosed after a significant delay. The
awareness campaign, such as the “HeadSmart” campaign in the United Kingdom (UK), can improve diagnostic times in Qatar.
Further research is required to better understand the reasons for the delay.
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Introduction
Primary CNS tumors are the largest group of solid tumors
occurring in children [1–3]. They are also associated with
the highest rate of cancer-related deaths in children [2, 4, 5].
The overall incidence of cancer and brain tumors in 0–14-
year-old children follows the same pattern in Qatar, as else-
where [6, 7]. Establishing the diagnosis of a CNS tumor is the
crucial first step before treatment can be initiated. A delay in
making a diagnosis can result in tumor progression, develop-
ment of hydrocephalus, and even tentorial herniation in rare
instances. If the diagnosis is delayed to the point that emer-
gency neurosurgical intervention is required, it can lead to
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catastrophic consequences including less than complete surgi-
cal removal of the tumor, higher surgical morbidity and poor
visual, and endocrine and neurocognitive long-term outcomes
[8–11].
Diagnosing CNS tumors in children is a challenge as they
are not associated with any unique diagnostic symptoms. The
most common symptoms of brain tumors are headache and
vomiting, which are common to many other childhood ill-
nesses [12]. Physicians are therefore faced with the difficult
decision of balancing the risk of delaying the diagnosis against
that of overinvestigation and causing unnecessary alarm for
the families. Identification of discriminatory symptoms can
help the diagnostic process. Several international studies have
examined the time to diagnosis of CNS tumors in children.
The median time to diagnosis varies from 20.5 days to several
months [13–22] (Table 1).
Qatar is a high-income developing country, with a popula-
tion of nearly 3 million [23]. Eighty-nine percent of residents
in Qatar are expatriates, with only 11% belonging to the in-
digenous Qatari population [24]. The proportion of Qatari
children in the 0–14 year age group, however, is 32.5%
[25]. The Qatar National Health Service covers the entire pop-
ulation through government funding and health insurance sys-
tem provided by employers. The physician to population ratio
and hospital beds to population ratio is among the best in the
region and comparable to most industrialized nations [26].
The population is mainly urban and has easy access to prima-
ry, secondary, and tertiary healthcare including neuroimaging
facilities.
According to the Qatar National Cancer Registry (QNCR)
data, the incidence of brain tumors in Qatar is 15% of all
childhood cancers among the 0–14-year age group [6].
Historically, children with CNS tumors in Qatar were treated
at the Hamad General Hospital (HGH), which is a large teach-
ing hospital that housed all relevant specialist services until
the recent restructuring of pediatric services with the commis-
sioning of Sidra Medicine in June 2018 as a tertiary care
women and children’s hospital. Follow-up and treatment of
all children with CNS tumors were transferred to Sidra
Medicine and Pediatric Neuro-Oncology service (PNOS) in
Qatar was also established.
There are no previous studies from Qatar reporting the
presenting symptoms or diagnostic times for pediatric CNS
tumors. We undertook this retrospective cohort study to re-
view the diagnosis of CNS tumors in children in Qatar to
analyze the presentation characteristics including symptoms,
referral pathways, and time to diagnosis.
Materials and methods
This is a retrospective cohort study. A review of electronic
medical records (EMR) was carried out after the approval by
the Institutional Review Board (IRB Number 1589712). All
children up to their 18th birthday in our database who were
diagnosed with a CNS tumor until the end of February 2020
were included in this study. As the majority (n = 29) had been
diagnosed prior to the establishment of PNOS, we reviewed
their medical records from the time of presentation at HGH.
The earliest patient in our database was diagnosed in October
2007. The study period therefore extends between October
2007 and February 2020. Age at the time of diagnosis, gender,
nationality (Qatari nationals vs. non-Qatari), and details of
pr imary hea l thcare contac t were a lso recorded .
Histopathological type (where available), location of the tu-
mor, presence of metastatic disease and presence of a
neurocutaneous syndrome were noted. All presenting symp-
toms recorded in the medical notes and length of time (in
days) each symptom had been present at the time of diagnosis
was noted and analyzed if there had been symptom progres-
sion through this period. The date of diagnosis was defined as
the date on which diagnostic neuroimaging was performed.
Pre-diagnosis symptom interval (PSI) was defined as the time
interval from the onset of the first symptom to the date of
diagnosis.
Table 1 Summary of recent published studies reporting diagnostic times for pediatric CNS tumors
Authors Year published Type of study Population (time period) Cohort size (age range in years) Mean PSI Median PSI
Reulecke et al. [13] 2008 Single center Germany (1980–2004) 245 (0–19.2) 59.3 days 24 days
Hayashi et al. [14] 2010 Multi-center Japan (1995–2008) 60 (1–15) Not reported 20.5 days
Wilne et al. [15] 2012 Multi-center UK (2004–2006) 139 (29 days–16.7 years) Not reported 3.3 months
Shay et al. [16] 2015 Single center Israel (1996–2004) 330 (0–18) 7.7 months Not reported
Stocco et al. [17] 2017 Single center Italy (2000–2012) 75 (0–16) Not reported 4 weeks
Azizi et al. [18] 2017 Single center Austria (2008–2013) 212 (0–19) Not reported 60 days
Boutaher et al. [19] 2018 Single center Morocco 2016 27 (1–15) Not reported 2 months
Gilli et al. [20] 2019 Single center Brazil (2005–2010) 192 (0–18) Not reported 48 days
Patel et al. [21] 2019 Single center USA (2008–2017) 235 (0–25) Not reported 42 days
Hirata et al. [22] 2020 Single center Japan (1984–2000) 85 (0–18) Not reported 45 days
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Statistical analysis
Patient characteristics are presented as numbers and percent-
ages for each characteristic. Both mean and median are pre-
sented for the pre-diagnosis symptom interval (PSI) outcome.
Because the data of PSI was highly skewed, bootstrap bias-
corrected (BCa) 95% confidence intervals (CI) were comput-
ed. Student’s t test based on 1000 bootstrap samples was used
to evaluate differences of PSI. All statistical assessments were
two sided and considered significant at p < 0.05. All analyses
were performed using Social Sciences for Windows (version
24, SPSS).
Results
Table 2 summarizes patient characteristics. After excluding
the 10 children who were either diagnosed outside Qatar (n
= 7) or were asymptomatic at the time of diagnosis (n = 3),
fifty-one children were included in the study. Eleven of these
patients were under active therapy at the time of inclusion in
this study. The median age at diagnosis was 45 months (range
1–171) with an equal gender ratio. Eighteen (35.3%) patients
belonged to the native Qatari population, while the remaining
33 (64.7%) were non-Qataris. Nine patients (17.6%) had
neurocutaneous syndromes (6 had tuberous sclerosis (TS)
and 3 had neurofibromatosis type 1 (NF)).
Tumor characteristics
Diagnosis for 37 patients (72.5%) was confirmed with histo-
pathology, whereas the remaining 14 (27.5%) patients were
diagnosed on neuroimaging alone (5 each with subependymal
giant cell astrocytoma (SEGA) and with optic pathway glioma
(OPG), 2 with (DIPG) and 2 with other LGG. The most com-
mon tumor type in our cohort was LGG (47%), followed by
medulloblastoma/primitive neuro-ectodermal tumor (PNET)
(23.5%), intracranial germ cell tumor (GCT) (9.8%), high-
grade glioma (HGG) (7.8%), and atypical teratoid rhabdoid
tumor (ATRT) (3.9%). Thirty (58.8%) tumors were in
supratentorial locations, 17 (33.3%) were infratentorial, and
4 (7.8%) in the spinal cord. Forty-two (82.4%) patients had
localized tumors at the time of presentation. The remaining 9
patients had multifocal (n = 7) or metastatic (n = 2) disease.
The two truly metastatic tumors included one case each of
medulloblastoma and GCT, whereas the 7 multifocal tumors
included 4 SEGA and 3 optic pathway glioma (OPG).
Referral pathways
Table 3 summarizes referral pathways for the diagnosis of
CNS tumors for our cohort. Thirty-eight (74.5%) had at least
one prior healthcare contact before the diagnostic imagingwas
initiated. Documented contacts included with Pediatric
Neurology (18), General Pediatrics (8), Primary Care Health
Centers (8), Pediatric Endocrinology (5), Pediatric Emergency
Centers (5), Ophthalmology/Opticians (4), Gastroenterology
(1), Cardiology (1), and Neurosurgery (1). Twenty-eight pa-
tients were seen by a single physician/team, 5 were seen by 2
teams, and 4 patients were seen by three different teams dur-
ing the symptom interval. Fourteen of the patients with prior
healthcare contact were eventually diagnosed through ED,
with an equal distribution of high- and low-grade tumors (7
each). The remaining 13 (25.4%) patients presented acutely to
the ED without any prior healthcare contact. Nine (62%) of
these had high-grade tumors (6 medulloblastoma, 2 DIPG,
and 1 ATRT).
Presenting symptoms
Figures 1 and 2 summarize the presenting symptoms in our
cohort. The median number of recorded symptoms was 2
(range 1–4). All patients had at least 1 symptom at the time
of diagnosis, 39 (76.4%) had two, 19 (37.2%) had three, while
7 (13.7%) patients had developed four symptoms by the time
the diagnosis was made.
The three most common presenting symptoms were head-
ache (37.2%), vomiting (33.3%), and ataxia and oculo-visual
symptoms (17.6% each). For children under 3 years of age,
the most common presenting symptom was irritability,
vomiting, and oculo-visual symptoms (27.2%). Headache
(62%), vomiting (37.9%), and ataxia (20.6%) were the pre-
dominant presenting symptoms for older children. Figure 2
shows the frequency of symptoms according to tumor loca-
tion. Supratentorial tumors presented most commonly with
vomiting (30%), headache, and seizures (26.6% each), where-
as the most common presenting symptoms for infratentorial
tumors were headache (64.7%), vomiting (47%), and ataxia
(41.1%). All spinal tumors presented with motor weakness (n
= 4), in addition to head tilt (1) and back pain (1).
Symptom progression
Symptom progression was seen in 19 (37.2%) patients. LGG
was the commonest tumor type, followed by medulloblasto-
ma, GCT, and DIPG. Three patients had other tumor types.
Median PSI was 36 days for patients who had symptom pro-
gression. Medulloblastoma and ATRT were associated with
the shortest PSI, whereas GCT and LGG had the longest PSI.
At symptom onset, the two most common symptoms were
headache (26%) and vomiting (21%). LGG had varied symp-
toms at onset as well as a diagnosis. Four of the five patients
with medulloblastoma had vomiting and 3 had headaches at
symptom onset. By the time the diagnosis was established, a
fourth patient had developed a headache, two had developed
ataxia, and two had developed other symptoms. Figure 3
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summarizes the pattern of symptom progression in the four
most common tumor types.
Pre-diagnosis symptom interval
Figure 4 and Tables 4 and 5 summarize the PSI analysis.
Median PSI was 28 days (range 1 to 845 days). Longest PSI
(median 146 days) was seen with GCT (median 146 days)
followed by LGG (median 45 days), HGG (median 25.5
days), and medulloblastoma/PNET (median 15 days). Age
below 3 years had shorter PSI (36 days vs 13.5 days for youn-
ger age group). Infratentorial tumor location (median 39.5
days vs. 15 days for infratentorial location, p = 0.049) and
high-grade tumor (45 days vs 15 days for high-grade tumor,
p = 0.040) were significantly associated with a shorter PSI.
For presenting symptoms, developmental delay (n = 2, me-
dian 455.5 days) was associated with the longest PSI, follow-
ed by endocrine symptoms (median 241 days), seizures (47
days), and oculo-visual symptoms (43 days). Irritability (8.0
days), vomiting (14.0 days), and headache (19 days) had the
shortest PSI. Raised ICP in our cohort was not associated with
shorter PSI. Ataxia (p = 0.039), head tilt (p = 0.021), and
altered consciousness (p = 0.018) were significantly associat-
ed with shorter PSI.
PSI according to the referral pathway was shorter for those
who were diagnosed through ED (19.0 days vs. 33.5 days for
those who were diagnosed through non-elective pathways).
This difference was not statistically significant (p = 0.113).
Discussion
This is the first report on primary CNS tumors in children
from Qatar. We have documented the presenting symptoms
and diagnostic times and highlighted some areas for future
research.
Presenting symptoms of CNS tumors depend on the pa-
tient’s age, tumor location, and its biological behavior.
Timely recognition of these symptoms can initiate the referral
process and avoid the anxiety and uncertainty of a lengthy
diagnostic process for the patient/family, and save the health
service precious time, personnel, and financial resources. Our
results showed symptoms of raised intracranial pressure in-
cluding headache, vomiting, lethargy, and visual disturbance
were common to children of all ages and all intracranial tu-
mors. In older children, headache and vomiting were the two
most commonly reported symptoms, followed by abnormal
gait and oculo-visual symptoms. In children younger than 3
years of age vomiting, irritability, ocular abnormalities, and
nonspecific symptoms including lethargy were more com-
monly seen. Infratentorial tumors were more commonly asso-
ciated with symptoms of raised intracranial pressure while
seizures were more common in supratentorial tumors. The
frequency of presenting symptoms in our cohort is similar to
most other published reports [27, 28]. Not surprisingly, the 4
children with spinal tumors in our cohort presented with
symptoms of motor weakness, back pain, and head tilt.
Median PSI of 28 days in our cohort compares favorably
with other published series (Table 5). Our results confirm that
known factors including presenting symptoms, location, and
Table 2 Patient characteristics
Characteristic Number (%)
Total Patients 51 (100)
Median age (range) 45 months (1–171)
Up to 3 years 20 (39.2)
3 to 10 years 22 (43.1)
Above 10 years 9 (17.6)
Gender
Male 26 (50.9)
Female 25 (49.1)
Nationality
Qatari Nationals 18 (35.3)
Non-Qatari Nationals 33 (64.7)
Neurocutaneous syndromes
Neurofibromatosis type 1 3 (5.6)
Tuberous sclerosis 6 (11.8)
None 42 (82.4)
Tumor location
Supratentorial 30 (58.8)
Infratentorial 17 (33.3)
Spinal 4 (7.8)
Tumor type
LGG 24 (47.05)
Medulloblastoma/PNET 12 (23.5)
Germ cell tumor 5(9.8)
HGG 4 (7.8)
CNS ATRT 2 (3.9)
Others 4 (7.8)
Localized/metastatic
Localized 42 (82.4)
Metastatic/multifocal 9 (17.6)
Intracranial pressure (ICP)
Normal 28 (54.9)
Raised 19 (37.3)
Data not available 4 (7.8)
ED vs. elective diagnosis
ED 27 (52.9)
Elective 24 (47.1)
LGG, low-grade glioma; PNET, primitive neuro-ectodermal tumor;
HGG, high-grade glioma; ATRT, atypical teratoid rhabdoid tumor; ED,
emergency department; others (n = 4): choroid plexus carcinoma, 1;
craniopharyngioma, 1; ependymoma, 1; and meningioma, 1
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grade of the tumor significantly influence PSI. Vomiting and
seizures were associated with short PSI, whereas endocrine
symptoms were associated with longer PSI. Rapidly growing
tumors and age group younger than three years were associ-
ated with a shorter PSI. In our cohort, patients with the meta-
static and multifocal disease were grouped together. Of the
two metastatic patients in this group, one with medulloblasto-
ma had a short PSI (15 days), while the other with GCT had a
long PSI (181 days). These results are consistent with previ-
ous reports of short PSI with higher stage medulloblastoma by
Halperin et al. [29, 30] and a long PSI associated with meta-
static GCT by Sethi et al. [31].
Previous studies have shown long PSI to result from delay
in referral for neuroimaging by physicians and to lack of ac-
cess to neuroimaging facilities, which may be secondary to
geographical, financial, or health service-related constraints.
Closeness to a tertiary center and ready access to neuroimag-
ing have previously been cited as determinants of early diag-
nosis [13, 14]. We believe that small population size, high
physician to population ratio, urban habitation, and easy
Table 3 Referral pathways
Elective referrals (24) Diagnosed through ED (27)
Prior HC contact Yes (24) Yes (14) No (13)
Median PSI (days) 33.5 19.0
39.5 14.0
Tumor grade
High grade (%) 3 (12.5) 7 (50) 9 (69.2)
Low grade (%) 21 (87.5) 7 (50) 4 (30.8)
Breakdown of prior HC contact Neuro: 12
Gen Peds, Neuro, Ophth: 2
PCHC: 3
Gen Peds, Endo: 1
Gen Peds, Neuro, Gastro: 1
Gen Peds, Neuro, Endo: 1
Gen Peds, Ophth: 1
Neuro, Cardio: 1
Ophth: 1
NS: 1
PCHC: 5
PEC: 5
Gen Peds, Endo: 2
Endo: 1
Neuro: 1
HC, healthcare; ED, emergency department; PSI, pre-diagnosis symptom interval; Neuro, pediatric neurology;
Gen Peds, general pediatrics;Ophth, pediatric ophthalmology; PCHC, primary care health center; Endo, pediatric
endocrinology;Gastro, pediatric gastroenterology;Cardio, pediatric cardiology;NS, neurosurgery;PEC, primary
emergency center
0 2 4 6 8 10 12 14 16 18 20
Headache (19)
Voming (17)
Oculovisual (9)
Motor Weakness (8)
Seizures (8)
Ataxia (9)
Cranial Nerve Palsy (7)
Irritability (7)
Endocrine (4)
Head Tilt (5)
Altered Consciousness (2)
Others (12)
Above 10 years 3-10 years Up to 3 years Total
Fig. 1 Frequency of presenting
symptoms according to age
(N = 51). Oculo-visual symptoms:
nystagmus, 3; poor vision, 3;
diplopia, 1; blurred vision, 1;
proptosis, 1; endocrine symp-
toms: polyuria, 1; polydypsia, 1;
precocious puberty, 1; short
stature, 1. Others: back pain, 1;
lethargy, 3; rash, 2; neck pain, 2;
weight loss, 2; poor oral intake, 1;
fever, 1
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access to neuroimaging are among the factors leading to short
PSI in our cohort.
Importance of early diagnosis
While there is a consensus that CNS tumors should be diag-
nosed without delay, an “ideal” or acceptable time for diag-
nosis of pediatric CNS tumors is far from clear. The presump-
tion that “early” diagnosis should lead to favorable outcomes
is not necessarily true, as tumor outcomes are increasingly
associated with tumor biology and metastatic stage.
Biologically aggressive tumors tend to present early without
being associated with improved survival. In fact, some studies
report a correlation of shorter PSI with poor survival [29, 30,
32, 33]. Nonetheless, the importance of early diagnosis can
also not be underestimated. A long PSI leads to symptom
progression, increased intracranial pressure, and development
of other specific symptoms related to the involved area of the
brain. End organ damage such as visual loss, hypopituitarism,
and permanent motor function or cognitive function loss are
0 2 4 6 8
Others
Oculovisual
Irritability
Motor Weakness
Voming
Ataxia
a. Low Grade Glioma (N=6)
At Onset At Diagnosis
0 1 2 3 4 5
Voming
Headache
Ataxia
Motor Weakness
Others
b. Medulloblastoma (N=5)
At Onset At Diagnosis
0 1 2 3
Headache
Endocrine
Voming
Altered Consciousness
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CN Palsy
c. Germ Cell Tumor (N= 3)
At Onset At Diagnosis
0 1 2 3
Headache
Voming
Head Tilt
Others
Ataxia
d. High Grade Glioma (N=2)
At Onset At Diagnosis
Fig. 3 Symptom progression for common tumor types (N = 19). Bar charts for 3 other patients (1 each with atypical teratoid/rhabdoid tumor (ATRT),
choroid plexus carcinoma, and meningioma) not shown
0 2 4 6 8 10 12 14 16 18 20
Headache (19)
Voming (17)
Oculovisual (9)
Motor Weakness (8)
Seizures (8)
Ataxia (9)
Cranial Nerve Palsy (7)
Irritability (7)
Endocrine (4)
Head Tilt (5)
Altered Consciousness (2)
Others (12)
Spinal Infratentorial Supratentorial Total
Fig. 2 Frequency of presenting
symptoms according to tumor
location (N = 51). Oculo-visual
symptoms: nystagmus, 3; poor
vision, 3; diplopia, 1; blurred
vision, 1; proptosis, 1; endocrine
symptoms: polyuria, 1;
polydypsia, 1; precocious puber-
ty, 1; short stature, 1. Others: back
pain, 1; lethargy, 3; rash, 2; neck
pain, 2; weight loss, 2; poor oral
intake, 1; fever, 1
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some of the other catastrophic sequelae of late diagnosis of a
brain tumor [8, 10]. Early recognition of presenting signs and
symptoms would lead to a timely diagnosis.
Some 20–30% of children with CNS tumors are diagnosed
after presenting acutely to the ED without any prior healthcare
contact due to their rapid rate of progression [15]. Our results
confirm this pattern of presentation. Additionally, 14 (27%) of
our patients were diagnosed through ED despite prior HC
contact. Patients presenting directly to ED had a shorter PSI
(14 days vs. 39 days) and a larger proportion of high-grade
tumors (62% vs. 50%) compared those who had prior
healthcare contact. Possible explanations for children with
Table 4 Pre-diagnosis symptom
interval (PSI) by patient and tu-
mor variables (N = 51)
Variable No. of cases (%) Mean (95% CI1) Median days p valuea
Age
Up to 3 years 22 (43.14) 85.50 (24.25–156.04) 13.50 0.594
Above 3 years 29 (56.86) 117.83 (58.34–188.68) 36.00
Sex
Male 26 (50.98) 98.19 (52.55–157.06) 26.50 0.838
Female 25 (49.02) 109.80 (31.70–189.86) 29.00
Nationality
Qatari Nationals 18 (35.29) 84.39 (27.48–176.35) 22.50 0.589
Non-Qatari Nationals 33 (64.71) 114.52 (57.17–183.70) 29.00
ED vs. elective diagnosis
ED 27 (52.94) 54.78 (30.75–83.52) 19.00 0.113
Elective 24 (47.06) 159.13 (62.18–278.60) 33.50
Tumor location
Supratentorial 30 (58.82) 148.07 (70.78–244.70) 39.50 0.049
Infratentorial 21 (41.18) 40.76 (19.21–69.74) 15.00
Tumor grade
Low-grade tumor 32 (62.75) 148.03 (79.57–223.46) 45.00 0.040
High-grade tumor 19 (37.25) 29.53 (16.76–43.00) 15.00
Localized vs. metastatic
Localized 42 (82.35) 82.29 (40.24–140.91) 26.50 0.230
Metastatic 9 (17.65) 204.67 (53.14–396.00) 90.00
Intracranial pressure (ICP)2
Raised 28 (59.57) 56.89 (33.47–85.04) 24.00 0.077
Normal 19 (40.43) 191.21 (82.40–331.04) 51.00
1 Bootstrap bias-corrected (BCa) 95% CI based on 1000 bootstrap samples
2 Data was available for 47 patients
a Independent sample t test based on 1000 bootstrap samples (significant values in italics)
Fig. 4 Boxplot of pre-diagnosis
symptom interval according to the
tumor type (N = 51). Median pre-
diagnostic symptom intervals
(PSI) according to tumor type:
atypical teratoid/rhabdoid tumor
(ATRT); low-grade glioma
(LGG); high-grade glioma
(HGG); medulloblastoma/
primitive neuro-ectodermal tumor
(PNET); intracranial germ cell
tumor (GCT)
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prior HC contact presenting to ED include lack of early rec-
ognition of presenting symptoms by the HC professionals and
a sudden deterioration in the clinical condition of the child.
Multiple visits to healthcare providers with the same or pro-
gressive symptoms are known to cause a perception of delay
that leads to undermining of trust in the healthcare profes-
sionals [34, 35].
These findings highlight the need for increased awareness
among the general public, primary care physicians, and other
healthcare professionals for signs and symptoms of CNS tu-
mors. Researchers in the United Kingdom found diagnostic
time for pediatric CNS tumors to be unacceptably long at 14.4
weeks in 2006. After a comprehensive investigative and con-
sultative process, evidence-accredited guidelines for clinicians
were published in 2008 [36]. A national campaign
“HeadSmart: Be brain tumour aware” was launched in 2011,
which has resulted in a significant reduction of diagnostic time
from 14.4 weeks in 2006 to 6.7 weeks in 2013 [17, 37, 38]. A
locally adapted similar campaign to educate parents and
healthcare professionals in all settings will be helpful in
Qatar to recognize the signs and symptoms of CNS tumors
and optimize diagnostic times. A high index of suspicion is
required in all settings for recognition of the potential of a
brain tumor as a possible diagnosis in children to avoid un-
necessary delay in diagnosis.
Conclusions
In Qatar, the diagnostic times for pediatric CNS tumors are
short and comparable to other recent reports from Japan,
Germany, and Austria. However, many children are still diag-
nosed with a significant delay particularly those presenting
with endocrine symptoms and slow-growing tumors.
Children with low-grade tumors may not be at risk of death
from a delay in diagnosis but can have devastating quality of
life (QoL) consequences including severe visual impairment
and avoidable lifelong need for hormone replacement.
Targeted awareness campaign such as HeadSmart can help
parents and physicians recognize signs and symptoms of
CNS tumors and reduce diagnostic times.
What this study adds
This is the first study of its kind from the state of Qatar and
provides a baseline for future research. In analyzing the diag-
nostic times, we have identified the groups of patients who are
at risk of diagnostic delay and long-term morbidity. Although
not a primary objective of this study, we have also been able to
document the pattern of pediatric CNS tumor presentation in
Qatar. Our results can be used in future epidemiological
research.
Limitations
Our data were subject to parental recall bias as defining the
exact symptom onset varies depending on parental health lit-
eracy, symptoms awareness, health-seeking behavior, family
support networks, and parental anxiety. In common with all
retrospective studies using medical notes, we were limited by
the quality of data recorded at the time of presentation. We
were unable to document the symptom progression in depth
due to the unavailability of pre-hospital healthcare records.
Details of primary care or outpatient visits before being re-
ferred for neuroimaging were missing, making it difficult in
some cases to determine the referral pathways and examine if
Table 5 Pre-diagnosis symptom
interval (PSI) by presenting
symptoms (N = 51)
Symptom No. of cases (%) Mean days (95% CI1) Median days (days) p valuea
Headache 19 (37.25) 93.68 (35.86–165.56) 19.00 0.793
Vomiting 17 (33.33) 82.00 (18.01–169.64) 14.00 0.585
Irritability 7 (13.73) 124.86 (3.42–394.55) 8.00 0.842
Oculo-visual 9 (17.65) 204.00 (26.34–417.87) 36.00 0.282
Ataxia 9 (17.65) 30.78 (11.70–53.58) 19.00 0.039
Developmental delay 2 (3.92) 455.50 (260.25–650.75) 455.50 0.280
Endocrine 4 (7.84) 339.75 (160.00–584.75) 241.00 0.080
Seizure(s) 8 (15.69) 137.13 (23.02–316.32) 39.00 0.732
Motor weakness 8 (15.69) 62.38 (17.38–129.04) 29.50 0.276
Head tilt 5 (9.80) 7.80 (3.81–11.50) 8.00 0.021
Cranial nerve palsy 2 (3.92) 97.00 (65.00–139.00) 97.00 0.942
Altered consciousness 2 (3.92) 7.00 (6.00–8.00) 7.00 0.018
General symptoms 12 (23.53) 86.75 (18.80–175.55) 14.50 0.703
1 Bootstrap bias-corrected (BCa) 95% CI based on 1000 bootstrap samples
a Independent sample t test based on 1000 bootstrap samples (significant values in italics)
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there was a delay at the physician or healthcare level. Some
data on original neuroimaging was unavailable making the
ICP data incomplete. These deficiencies will be addressed in
a future prospectively designed study with a larger cohort.
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